The Community Guide

- gsearch

Search Results

Narrow Results:

2022 1
2019 1

CHeCS Investigators 1

United States 1

Journal Article 2

1 - 2 of 2 Results

Refine Results

Refine Results:

Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure

CITE Title : Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure Personal Author(s) : Lu, Mei;Wu, Kuan-Han;Li, Jia;Moorman, Anne C.;Spradling, Philip R.;Teshale, Eyasu H.;Boscarino, Joseph A.;Daida, Yihe G.;Schmidt, Mark A.;Rupp, Loralee B.;Zhang, Talan;Trudeau, Sheri;Gordon, Stuart C.; Published Date : July 04 2019 Source : J Viral Hepat. 26(10):1210-1217 URL : https://stacks.cdc.gov/view/cdc/94458 Lu, Mei et al. (2019). Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. 26(10). Lu, Mei et al. "Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure" 26, no. 10 (2019) Lu, Mei et al. "Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure" vol. 26, no. 10, 2019 Export RIS Citation Information.

:

Lu, Mei ;

Wu, Kuan-Han

July 04 2019 | J Viral Hepat. 26(10):1210-1217

:

The role of ribavirin (RBV) in the era of direct-acting antivirals (DAA) is not clear, and DAA studies have been largely genotype- and regimen-specifi...
Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006–2016)

CITE Title : Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006–2016) Personal Author(s) : Lu, Mei;Li, Jia;Zhou, Yueren;Rupp, Loralee B.;Moorman, Anne C.;Spradling, Philip R.;Teshale, Eyasu H.;Boscarino, Joseph A.;Daida, Yihe G.;Schmidt, Mark A.;Trudeau, Sheri;Gordon, Stuart C.; Corporate Authors(s) : CHeCS Investigators Published Date : 03/01/2022 Source : J Clin Gastroenterol. 56(3):273-279 URL : https://stacks.cdc.gov/view/cdc/129851 Lu, Mei et al. (2022). Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006–2016). 56(3). Lu, Mei et al. "Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006–2016)" 56, no. 3 (2022) Lu, Mei et al. "Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006–2016)" vol. 56, no. 3, 2022 Export RIS Citation Information.

:

Lu, Mei ;

Li, Jia

03/01/2022 | J Clin Gastroenterol. 56(3):273-279

:

Background:Changing US demographics and evolving chronic hepatitis B (CHB) treatments may affect longitudinal trends in CHB-related complications. We ...